CITIUS ONCOLOGY, INC.
For the period ended Dec 31, 2025. Filed Feb 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2025 · Filed Feb 13, 2026
CTOR$0.55+7.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| 4.1 | Form of Common Warrant (incorporated by reference to Exhibit 4.1 of Form 8-K filed on December 10, 2025). |
| 4.2 | Form of Pre-funded Warrant (incorporated by reference to Exhibit 4.2 of Form 8-K filed on December 10, 2025). |
| 4.3 | Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.3 of Form 8-K filed on December 10, 2025). |
| 10.1 | Form of Registered Direct Securities Purchase Agreement, dated as of December 9, 2025, by and between Citius Oncology, Inc. and the purchaser signatory thereto (incorporated by reference to Exhibit 10.1 of Form 8-K filed on December 10, 2025). |
| 10.2 | Form of PIPE Securities Purchase Agreement, dated as of December 9, 2025, by and between Citius Oncology, Inc. and the purchaser signatory thereto (incorporated by reference to Exhibit 10.2 of Form 8-K filed on December 10, 2025). |
| 10.3 | Form of Registration Rights Agreement, dated as of December 9, 2025, by and between Citius Oncology, Inc. and the purchaser signatory thereto (incorporated by reference to Exhibit 10.3 of Form 8-K filed on December 10, 2025). |
| 10.4 | Form of Warrant Amendment Agreement, dated as of December 9, 2025, by and between Citius Oncology, Inc. and the investor signatory thereto (incorporated by reference to Exhibit 10.4 of Form 8-K filed on December 10, 2025). |
| 10.5 | Amendment to Promissory Note, dated December 10, 2025, by and between Citius Oncology, Inc. and Citius Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.5 of Form 8-K filed on December 10, 2025). |
| 31.1 | Certification of the Principal Executive Officer pursuant to Exchange Act Rule 13a-14(a).* |
| 31.2 | Certification of the Principal Financial Officer pursuant to Exchange Act Rule 13a-14(a).* |
| 32.1 | Certification of the Principal Executive and Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002.* |
| EX-101.INS | Inline XBRL Instance Document* |
| EX-101.SCH | Inline XBRL Taxonomy Extension Schema Document* |
| EX-101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document* |
| EX-101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document* |
| EX-101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document* |
| EX-101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document* |
| EX-104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)* |
| * | Filed herewith. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.